Komori
Eiken Chemical (4549) · PolicyRestated

Practicing Social Responsibility and Living in Harmony with Society

First written in FY2016. 6 of 9 entries say "Restated". Latest entry: 2026-07-24.

9entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2020RestatedFY2023-Q1 – 2026-07-242016: 120162017: 020172018: 020182019: 020192020: 120202021: 020212022: 420222023: 220232024: 020242025: 020252026: 12026
Same theme, other companies
Sustainability Management, ESG, Materiality and Information DisclosureA theme 624 companies write about · 1 as a headwind · 655 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 184 companies compared. The sentences above are computed from all 184.Comparing 200 of the theme's 656 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-07-24RestatedOther Disclosures

    「Under the management philosophy “Protecting people’s health through healthcare,” the Group has strengthened its ESG initiatives based on its sustainability policy. Through this selection, we will continue to fulfil our responsibilities to stakeholders by actively addressing issues in “healthcare,” “environment,” “social” and “governance” through our business activities as a company that protects the health of people worldwide, with the aim of enhancing corporate value and ultimately realising a sustainable society.」

    The company reiterated its sustainability policy based on ESG initiatives and reported being selected for the FTSE JPX Blossom Japan Index for the second consecutive year and the FTSE JPX Blossom Japan Sector Relative Index for the fourth consecutive year.
  2. FY2024-Q1RestatedAnnual report

    「As a company that protects the health of people around the world, we are actively addressing issues in healthcare as well as environmental, social and governance issues, while seeking to further enhance corporate value and help realize a sustainable society.」

    The Company continues its policy of addressing environmental, social and governance issues in addition to healthcare, with the aim of enhancing corporate value and helping realize a sustainable society.
  3. FY2023-Q3RestatedAnnual report

    「As a company that protects the health of people around the world, we are actively addressing issues in healthcare as well as environmental, social and governance issues, while seeking to further enhance corporate value and help realize a sustainable society by resolving social issues.」

    The Company continues its policy of addressing environmental, social and governance issues in addition to healthcare, with the aim of enhancing corporate value and helping realize a sustainable society through the resolution of social issues.
  4. FY2023-Q2RestatedAnnual report

    「As a company that protects the health of people around the world, we are actively addressing issues in healthcare as well as environmental, social and governance issues, while seeking to further enhance corporate value and help realize a sustainable society by resolving social issues.」

    The Company continues its policy of addressing environmental, social and governance issues in addition to healthcare, with the aim of enhancing corporate value and helping realize a sustainable society through the resolution of social issues.
  5. FY2023-Q1RestatedAnnual report

    「As a company that protects the health of people around the world, we are actively addressing issues in healthcare as well as environmental, social and governance issues, while seeking to further enhance corporate value and help realize a sustainable society by resolving social issues.」

    The Company continues its policy of addressing environmental, social and governance issues in addition to healthcare, with the aim of enhancing corporate value and helping realize a sustainable society.
  6. FY2022AdvancedAnnual report

    「To promote sustainability more actively across the Group, the Company formulated a sustainability policy and established a Sustainability Committee, chaired by the Representative Executive Officer, President, and comprising the executive officers responsible for each function and business group, to drive related initiatives.」

    The Company established a sustainability policy and committee and put in place a company-wide framework, including reporting to and oversight by the Board of Directors. It also identified 11 materialities and presented a framework for managing progress using KPIs.
  7. FY2022-Q3AdvancedAnnual report

    「In addition, fixed liabilities increased by 3,015 million yen, mainly because in October 2021 the Company issued its first sustainability bond, amounting to 3,000 million yen, to raise funds for measures and projects contributing to the resolution of environmental and social issues.」

    The response to environmental and social issues is described in connection with financing raised through the Company’s first sustainability bond issuance.
  8. FY2020RestatedAnnual report

    「In the medical field, measures to address COVID-19 remain the highest priority. Guided by its management philosophy, “Protecting people’s health through healthcare,” the Group will continue to contribute to healthcare by, among other measures, establishing a system for the stable supply of COVID-19 detection reagents.」

    The policy of contributing to healthcare through healthcare services is described in connection with establishing a system for the stable supply of COVID-19 detection reagents.
  9. FY2016First statedAnnual report

    「⑤ Fulfilling Social Responsibility and Harmonizing with Society」

    This is set out as a policy covering information management, the Corporate Governance Code, transparency in funding provided to healthcare professionals, environmental activities and other matters.
Moved together

"Accelerating Global Expansion" moved the same way as this thread, in the same document, in 2 of its 9 moves.

22222★12345
  1. ★This thread
  2. 1Accelerating Global Expansion2×
  3. 2Market Expansion of Fecal Occult Blood and Urine Testing Products in Overseas Markets2×
  4. 3Expansion of Production Capacity and Construction of a New Manufacturing Facility2×
  5. 4Contribution of COVID-19-Related Products to Sales and Profit2×
  6. 5Sluggish Overseas Sales Growth and Stagnation in North American Fecal Occult Blood Products2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Eiken Chemical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the Other Disclosures of 2026-07-24: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Practicing Social Responsibility and Living in Harmony with Society | EIKEN CHEMICAL CO.,LTD. (4549) | Komori